Matteo Zampini
Overview
Explore the profile of Matteo Zampini including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
340
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oliva E, Cuzzola M, Porta M, Candoni A, Salutari P, Palumbo G, et al.
Int J Mol Sci
. 2024 Nov;
25(21).
PMID: 39519198
The achievement of complete remission (CR) is crucial for acute myeloid leukemia (AML) patients undertaking curative therapy, but relapse often occurs within months, highlighting the need for strategies to prolong...
2.
DAmico S, DallOlio D, Sala C, DallOlio L, Sauta E, Zampini M, et al.
JCO Clin Cancer Inform
. 2023 Jun;
7:e2300021.
PMID: 37390377
Purpose: Synthetic data are artificial data generated without including any real patient information by an algorithm trained to learn the characteristics of a real source data set and became widely...
3.
Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao L, et al.
J Clin Oncol
. 2023 Mar;
41(15):2827-2842.
PMID: 36930857
Purpose: Myelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was...
4.
Chiereghin C, Travaglino E, Zampini M, Saba E, Saitta C, Riva E, et al.
Genes (Basel)
. 2021 Aug;
12(8).
PMID: 34440317
Myelodysplastic syndromes (MDS) are a clonal disease arising from hematopoietic stem cells, that are characterized by ineffective hematopoiesis (leading to peripheral blood cytopenia) and by an increased risk of evolution...
5.
Rossi M, Meggendorfer M, Zampini M, Tettamanti M, Riva E, Travaglino E, et al.
Blood
. 2021 Jun;
138(21):2093-2105.
PMID: 34125889
Clonal hematopoiesis of indeterminate potential (CHIP) is associated with increased risk of cancers and inflammation-related diseases. This phenomenon becomes common in persons aged ≥80 years, in whom the implications of...
6.
Bersanelli M, Travaglino E, Meggendorfer M, Matteuzzi T, Sala C, Mosca E, et al.
J Clin Oncol
. 2021 Feb;
39(11):1223-1233.
PMID: 33539200
Purpose: Recurrently mutated genes and chromosomal abnormalities have been identified in myelodysplastic syndromes (MDS). We aim to integrate these genomic features into disease classification and prognostication. Methods: We retrospectively enrolled...
7.
Zampini M, Tregnago C, Bisio V, Simula L, Borella G, Manara E, et al.
Leukemia
. 2018 Feb;
32(5):1124-1134.
PMID: 29472719
The somatic translocation t(8;21)(q22;q22)/RUNX1-RUNX1T1 is one of the most frequent rearrangements found in children with standard-risk acute myeloid leukemia (AML). Despite the favorable prognostic role of this aberration, we recently...
8.
Zampini M, Bisio V, Leszl A, Putti M, Menna G, Rizzari C, et al.
Br J Haematol
. 2017 Sep;
183(2):298-301.
PMID: 28961307
No abstract available.
9.
Fernando T, Contreras J, Zampini M, Rodriguez-Malave N, Alberti M, Anguiano J, et al.
Mol Cancer
. 2017 Jul;
16(1):126.
PMID: 28724437
Background: Long non-coding RNAs (lncRNAs) play a variety of cellular roles, including regulation of transcription and translation, leading to alterations in gene expression. Some lncRNAs modulate the expression of chromosomally...
10.
Tombolan L, Zampini M, Casara S, Boldrin E, Zin A, Bisogno G, et al.
PLoS One
. 2015 Apr;
10(4):e0125171.
PMID: 25915942
Background: Rhabdomyosarcomas (RMS) are rare but very aggressive childhood tumors that arise as a consequence of a regulatory disruption in the growth and differentiation pathways of myogenic precursor cells. According...